Francisco Jiménez-Oñate

Francisco Jiménez-Oñate

Auto-generated profile, based on publicly available information

Francisco Jiménez-Oñate

Department of Infectious Disease, Hospital Regional Universitario de Málaga, Malaga, Spain

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2007 in JAIDS Journal of Acquired Immune Deficiency Syndromes
Verified
Journal Article
Closed access
RPRosario Palacios
Rosario Palacios
FJFrancisco Jiménez-Oñate
Francisco Jiménez-Oñate
MAManuela Aguilar
Manuela Aguilar
MGMa José Galindo
Ma José Galindo
PRPablo Rivas
Pablo Rivas
JSJesús Santos
Jesús Santos
To assess the effect of early syphilis on HIV viral load (VL) and CD4 cell count in patients with HIV and to analyze factors associated with changes in HIV VL and CD4 cell count. Multicenter study of a series of patients with HIV who were diagnosed with early syphilis infection during 2004 through 2005. Patients who started or changed their highly active antiretroviral therapy (HAART) regimen during the analysis period were excluded. One hundred eighteen patients were analyzed: 95.8% were men, mean patient age was 38.2 years, 83.9% were homosexual men, 50.8% were on antiretroviral therapy at the time syphilis was diagnosed, and HIV and syphilis diagnoses were coincident in 38 (32.2%) cases. CD4 cell counts were lower during syphilis than before (590 vs. 496 cells/microL; P = 0.0001) and after syphilis treatment (509 vs. 597 cells/microL; P = 0.0001). The HIV VL increased in 27.6% of patients during syphilis. The only factor associated with an HIV VL increase was not being on HAART, and the only factor associated with a CD4 count decrease >100 cells/microL during syphilis was the prior CD4 cell count. Syphilis infection was associated with a decrease in the CD4 cell count and an increase in the HIV VL in almost one third of the patients. In this series, more than two thirds of the syphilis cases were diagnosed in patients who were previously known to be infected with HIV.

1 December 2005 in Lung
Verified
Journal Article
Closed access
PDF file
ESEnrique J. Soto-Hurtado
Enrique J. Soto-Hurtado
EMEster Marín-Gámez
Ester Marín-Gámez
NSNuria Segura-Domínguez
Nuria Segura-Domínguez
FJFrancisco Jiménez-Oñate
Francisco Jiménez-Oñate

1 February 2014 in HIV Research & Clinical Practice
Verified
Journal Article
Closed access
JTJavier de la Torre-Lima
Javier de la Torre-Lima
AAAna Aguilar
Ana Aguilar
JSJesus Santos
Jesus Santos
FJFrancisco Jiménez-Oñate
Francisco Jiménez-Oñate
MMMiguel Marcos
Miguel Marcos
MGMálaga Infectious Disease Group
Málaga Infectious Disease Group
Background: To study the durability of the drugs and coformulations currently used in the first treatment regimen of antiretroviral therapy (ART) for HIV patients, and to examine the reasons for changing this medication. Methods: A retrospective observational multicenter study of patients with HIV infection who started a first-line ART regimen between January 2007 and June 2010. The primary outcome variable was the durability of this first ART regimen until discontinued or amended and the reasons for the change. Survival analysis of durability was performed using Kaplan-Meyer curves analysis, and a Cox multiple regression model was constructed to identify associated factors. Results: A first-line ART regimen was initiated for 600 patients; after 1 year, it had been changed in 172 (28%) cases, with a median duration of 31 months. The main reason for change was toxicity (20.5% of all patients), followed by loss to follow-up (8.3%) and virological failure (5.3%). The most common type of toxicity was gastrointestinal (30%), followed by cutaneous (23%) and neuropsychiatric (18%). The use of non-nucleoside reverse transcriptase inhibitors (NNRTIs) was associated with greater durability than that of protease inhibitors (43 months vs 21 months; P = .001). Conclusions: The durability of the first-line ART regimen, based on current antiretroviral drugs and coformulations, is about 2.5 years, with toxicity being the main reason for its modification. Gastrointestinal toxicity is the type most commonly reported. NNRTI treatment is associated with greater durability of the first treatment regimen.

1 February 2015 in Enfermedades Infecciosas y Microbiología Clínica
Verified
Journal Article
Closed access
LPLuis Miguel Pérez-Belmonte
Luis Miguel Pérez-Belmonte
EMElisabeth Gómez Moyano
Elisabeth Gómez Moyano
LHLeticia Herrero-Lifona
Leticia Herrero-Lifona
FJFrancisco Jiménez-Oñate
Francisco Jiménez-Oñate

31 October 2009 in Medicina Clinica
Verified
Journal Article
Closed access
EMElisabeth Gómez Moyano
Elisabeth Gómez Moyano
AGAlicia Hiraldo Gamero
Alicia Hiraldo Gamero
ATAndrés Sanz Trelles
Andrés Sanz Trelles
FOFrancisco Jiménez Oñate
Francisco Jiménez Oñate

1 November 2011 in Journal of the International Association of Physicians in AIDS Care
Verified
Journal Article
Closed access
RPRosario Palacios
Rosario Palacios
TMTamara Moreno
Tamara Moreno
MGMarisa Gallego
Marisa Gallego
AAAlfonso del Arco
Alfonso del Arco
FJFrancisco Jiménez-Oñate
Francisco Jiménez-Oñate
TIThe Sociedad Andaluza de Enfermedades Infecciosas
The Sociedad Andaluza de Enfermedades Infecciosas